CL King initiated coverage of Integra LifeSciences with a Buy rating and $50 price target. The firm believes the stock price is currently depressed due to the Boston recall and FDA Warning Letter, but as the company proceeds with its remediation plans, the stock price should move higher, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences price target lowered to $39 from $41 at Truist
- Integra LifeSciences price target lowered to $40 from $47 at Wells Fargo
- Integra LifeSciences sees Q4 adjusted EPS 89c-93c, consensus 92c
- Integra LifeSciences narrows FY23 EPS view to $3.10-$3.14 from $3.10-$3.18
- Integra LifeSciences reports Q3 adjusted EPS 76c, consensus 78c